A Soluble LAG-3 Protein (Eftilagimod Alpha) with an Anti-PD-1 Antibody (Pembrolizumab): Results of a Phase II Study in NSCLC

Time: 9:00 am
day: Day Two

Details:

  • An MHC class II agonist (eftilagimod) used as an antigen presenting cell (APC) activator combined with an immune checkpoint inhibitor (ICI): a unique combination in immuno-oncology
  • Results in first and second (in PD-X refractory patients) lines non-small cell lung carcinoma (NSCLC)

Speakers: